valproic acid has been researched along with Carcinoma, Non-Small Cell Lung in 15 studies
Valproic Acid: A fatty acid with anticonvulsant and anti-manic properties that is used in the treatment of EPILEPSY and BIPOLAR DISORDER. The mechanisms of its therapeutic actions are not well understood. It may act by increasing GAMMA-AMINOBUTYRIC ACID levels in the brain or by altering the properties of VOLTAGE-GATED SODIUM CHANNELS.
valproic acid : A branched-chain saturated fatty acid that comprises of a propyl substituent on a pentanoic acid stem.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Patients were treated with escalating doses of decitabine (5-15 mg/m(2)) IV for 10 days in combination with VPA (10-20 mg/kg/day) PO on days 5-21 of a 28-day cycle." | 2.78 | Phase I study of 5-aza-2'-deoxycytidine in combination with valproic acid in non-small-cell lung cancer. ( Aimiuwu, J; Chan, KK; Chu, BF; Grever, MR; Karpenko, MJ; Liu, Z; Otterson, GA; Villalona-Calero, MA, 2013) |
| "Lung cancer is the most frequent cause of cancer death." | 1.72 | Tumors derived from lung cancer cells respond differently to treatment with sodium valproate (a HDAC inhibitor) in a chicken embryo chorioallantoic membrane model. ( Balnytė, I; Diržiuvienė, R; Lasienė, K; Palubinskienė, J; Šlekienė, L; Stakišaitis, D; Valančiūtė, A, 2022) |
| " In this paper, we have investigated the cytotoxic interaction of ERL and valproic acid (VA) in ERL-resistant NSCLC cells and developed a liquisolid formulation of ERL-VA for improving oral bioavailability of ERL." | 1.51 | Erlotinib-Valproic Acid Liquisolid Formulation: Evaluating Oral Bioavailability and Cytotoxicity in Erlotinib-Resistant Non-small Cell Lung Cancer Cells. ( Bagde, A; Doddapaneni, R; Patel, K; Patki, M; Sekar, V; Singh, M, 2019) |
| "Valproic acid (VPA) has been suggested to be a histone deacetylase inhibitor (HDACI)." | 1.46 | Valproic acid (VPA) enhances cisplatin sensitivity of non-small cell lung cancer cells via HDAC2 mediated down regulation of ABCA1. ( Chen, JH; Ding, ZL; Fu, R; Gu, LZ; Hu, CP; Qin, L; Wan, YF; Wang, Y; Xu, CQ; Zheng, YL, 2017) |
| " Oral dosing of mice results in absorption of intact prodrug with slow systemic hydrolysis yielding higher plasma levels of LY2334737 than gemcitabine and prolonged gemcitabine exposure." | 1.39 | Efficacy of low-dose oral metronomic dosing of the prodrug of gemcitabine, LY2334737, in human tumor xenografts. ( Dantzig, AH; Donoho, GP; Durland-Busbice, S; Perkins, EJ; Pratt, SE; Shepard, RL; Starling, JJ; Wickremsinhe, ER, 2013) |
| " The abovementioned activity of VPA as a differentiation agent suggested that it might be worth investigating its possible therapeutic potential in synergistic combination with FTS." | 1.37 | Downregulation of survivin and aurora A by histone deacetylase and RAS inhibitors: a new drug combination for cancer therapy. ( Biran, A; Brownstein, M; Haklai, R; Kloog, Y, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (6.67) | 29.6817 |
| 2010's | 13 (86.67) | 24.3611 |
| 2020's | 1 (6.67) | 2.80 |
| Authors | Studies |
|---|---|
| Diržiuvienė, R | 1 |
| Šlekienė, L | 1 |
| Palubinskienė, J | 1 |
| Balnytė, I | 1 |
| Lasienė, K | 1 |
| Stakišaitis, D | 1 |
| Valančiūtė, A | 1 |
| Patel, K | 1 |
| Doddapaneni, R | 1 |
| Patki, M | 1 |
| Sekar, V | 1 |
| Bagde, A | 1 |
| Singh, M | 1 |
| Du, XZ | 1 |
| Li, QY | 1 |
| Du, FW | 1 |
| He, ZG | 1 |
| Wang, J | 1 |
| Shirsath, N | 1 |
| Rathos, M | 1 |
| Chaudhari, U | 1 |
| Sivaramakrishnan, H | 1 |
| Joshi, K | 1 |
| Gavrilov, V | 1 |
| Lavrenkov, K | 1 |
| Ariad, S | 1 |
| Shany, S | 1 |
| Ciardiello, C | 1 |
| Roca, MS | 1 |
| Noto, A | 1 |
| Bruzzese, F | 1 |
| Moccia, T | 1 |
| Vitagliano, C | 1 |
| Di Gennaro, E | 1 |
| Ciliberto, G | 1 |
| Roscilli, G | 1 |
| Aurisicchio, L | 1 |
| Marra, E | 1 |
| Mancini, R | 1 |
| Budillon, A | 1 |
| Leone, A | 1 |
| Carter, CA | 1 |
| Zeman, K | 1 |
| Day, RM | 1 |
| Richard, P | 1 |
| Oronsky, A | 1 |
| Oronsky, N | 1 |
| Lybeck, M | 1 |
| Scicinski, J | 1 |
| Oronsky, B | 1 |
| Aebischer, B | 1 |
| Elsig, S | 1 |
| Taeymans, J | 1 |
| Pomp, S | 1 |
| Kuhness, D | 1 |
| Barcaro, G | 1 |
| Sementa, L | 1 |
| Mankad, V | 1 |
| Fortunelli, A | 1 |
| Sterrer, M | 1 |
| Netzer, FP | 1 |
| Surnev, S | 1 |
| Schmieder, AH | 1 |
| Caruthers, SD | 1 |
| Keupp, J | 1 |
| Wickline, SA | 1 |
| Lanza, GM | 1 |
| Lowe, J | 1 |
| Wodarcyk, AJ | 1 |
| Floyd, KT | 1 |
| Rastogi, N | 1 |
| Schultz, EJ | 1 |
| Swager, SA | 1 |
| Chadwick, JA | 1 |
| Tran, T | 1 |
| Raman, SV | 1 |
| Janssen, PM | 1 |
| Rafael-Fortney, JA | 1 |
| Alcalay, RN | 1 |
| Levy, OA | 1 |
| Wolf, P | 1 |
| Oliva, P | 1 |
| Zhang, XK | 1 |
| Waters, CH | 1 |
| Fahn, S | 1 |
| Kang, U | 1 |
| Liong, C | 1 |
| Ford, B | 1 |
| Mazzoni, P | 1 |
| Kuo, S | 1 |
| Johnson, A | 1 |
| Xiong, L | 1 |
| Rouleau, GA | 1 |
| Chung, W | 1 |
| Marder, KS | 1 |
| Gan-Or, Z | 1 |
| Kamei, K | 1 |
| Terao, T | 1 |
| Katayama, Y | 1 |
| Hatano, K | 1 |
| Kodama, K | 1 |
| Shirahama, M | 1 |
| Sakai, A | 1 |
| Hirakawa, H | 1 |
| Mizokami, Y | 1 |
| Shiotsuki, I | 1 |
| Ishii, N | 1 |
| Inoue, Y | 1 |
| Akboga, MK | 1 |
| Yayla, C | 1 |
| Balci, KG | 1 |
| Ozeke, O | 1 |
| Maden, O | 1 |
| Kisacik, H | 1 |
| Temizhan, A | 1 |
| Aydogdu, S | 1 |
| Zhu, J | 2 |
| Ying, SH | 1 |
| Feng, MG | 1 |
| Zhang, XG | 1 |
| Li, H | 1 |
| Wang, L | 1 |
| Hao, YY | 1 |
| Liang, GD | 1 |
| Ma, YH | 1 |
| Yang, GS | 1 |
| Hu, JH | 1 |
| Pfeifer, L | 1 |
| Goertz, RS | 1 |
| Neurath, MF | 1 |
| Strobel, D | 1 |
| Wildner, D | 1 |
| Lin, JT | 1 |
| Yang, XN | 1 |
| Zhong, WZ | 1 |
| Liao, RQ | 1 |
| Dong, S | 1 |
| Nie, Q | 1 |
| Weng, SX | 1 |
| Fang, XJ | 1 |
| Zheng, JY | 1 |
| Wu, YL | 1 |
| Řezanka, T | 1 |
| Kaineder, K | 1 |
| Mezricky, D | 1 |
| Řezanka, M | 1 |
| Bišová, K | 1 |
| Zachleder, V | 1 |
| Vítová, M | 1 |
| Rinker, JA | 1 |
| Marshall, SA | 1 |
| Mazzone, CM | 1 |
| Lowery-Gionta, EG | 1 |
| Gulati, V | 1 |
| Pleil, KE | 1 |
| Kash, TL | 1 |
| Navarro, M | 1 |
| Thiele, TE | 1 |
| Zhang, Y | 1 |
| Huang, Y | 1 |
| Jin, Z | 1 |
| Li, X | 1 |
| Li, B | 1 |
| Xu, P | 1 |
| Huang, P | 1 |
| Liu, C | 1 |
| Fokdal, L | 1 |
| Sturdza, A | 1 |
| Mazeron, R | 1 |
| Haie-Meder, C | 1 |
| Tan, LT | 1 |
| Gillham, C | 1 |
| Šegedin, B | 1 |
| Jürgenliemk-Schultz, I | 1 |
| Kirisits, C | 1 |
| Hoskin, P | 1 |
| Pötter, R | 1 |
| Lindegaard, JC | 1 |
| Tanderup, K | 1 |
| Levin, DE | 1 |
| Schmitz, AJ | 1 |
| Hines, SM | 1 |
| Hines, KJ | 1 |
| Tucker, MJ | 1 |
| Brewer, SH | 1 |
| Fenlon, EE | 1 |
| Álvarez-Pérez, S | 1 |
| Blanco, JL | 1 |
| Peláez, T | 1 |
| Martínez-Nevado, E | 1 |
| García, ME | 1 |
| Puckerin, AA | 1 |
| Chang, DD | 1 |
| Subramanyam, P | 1 |
| Colecraft, HM | 1 |
| Dogan, H | 1 |
| Coteli, E | 1 |
| Karatas, F | 1 |
| Ceylan, O | 1 |
| Sahin, MD | 1 |
| Akdamar, G | 1 |
| Kryczyk, A | 1 |
| Żmudzki, P | 1 |
| Hubicka, U | 1 |
| Giovannelli, D | 1 |
| Chung, M | 1 |
| Staley, J | 1 |
| Starovoytov, V | 1 |
| Le Bris, N | 1 |
| Vetriani, C | 1 |
| Chen, W | 1 |
| Wu, L | 1 |
| Liu, X | 1 |
| Shen, Y | 1 |
| Liang, Y | 1 |
| Tan, H | 1 |
| Yang, Y | 1 |
| Liu, Q | 1 |
| Wang, M | 1 |
| Liu, L | 1 |
| Wang, X | 1 |
| Liu, B | 1 |
| Liu, GH | 1 |
| Zhu, YJ | 1 |
| Wang, JP | 1 |
| Che, JM | 1 |
| Chen, QQ | 1 |
| Chen, Z | 1 |
| Maucksch, U | 1 |
| Runge, R | 1 |
| Wunderlich, G | 1 |
| Freudenberg, R | 1 |
| Naumann, A | 1 |
| Kotzerke, J | 1 |
| Chen, JH | 1 |
| Zheng, YL | 1 |
| Xu, CQ | 1 |
| Gu, LZ | 1 |
| Ding, ZL | 1 |
| Qin, L | 1 |
| Wang, Y | 1 |
| Fu, R | 1 |
| Wan, YF | 1 |
| Hu, CP | 1 |
| Moody, TW | 1 |
| Switzer, C | 1 |
| Santana-Flores, W | 1 |
| Ridnour, LA | 1 |
| Berna, M | 1 |
| Thill, M | 1 |
| Jensen, RT | 1 |
| Sparatore, A | 1 |
| Del Soldato, P | 1 |
| Yeh, GC | 1 |
| Roberts, DD | 1 |
| Giaccone, G | 1 |
| Wink, DA | 1 |
| Biran, A | 1 |
| Brownstein, M | 1 |
| Haklai, R | 1 |
| Kloog, Y | 1 |
| Chu, BF | 1 |
| Karpenko, MJ | 1 |
| Liu, Z | 1 |
| Aimiuwu, J | 1 |
| Villalona-Calero, MA | 1 |
| Chan, KK | 1 |
| Grever, MR | 1 |
| Otterson, GA | 1 |
| Singh, T | 1 |
| Prasad, R | 1 |
| Katiyar, SK | 1 |
| Pratt, SE | 1 |
| Durland-Busbice, S | 1 |
| Shepard, RL | 1 |
| Donoho, GP | 1 |
| Starling, JJ | 1 |
| Wickremsinhe, ER | 1 |
| Perkins, EJ | 1 |
| Dantzig, AH | 1 |
| Ziauddin, MF | 1 |
| Yeow, WS | 1 |
| Maxhimer, JB | 1 |
| Baras, A | 1 |
| Chua, A | 1 |
| Reddy, RM | 1 |
| Tsai, W | 1 |
| Cole, GW | 1 |
| Schrump, DS | 1 |
| Nguyen, DM | 1 |
2 reviews available for valproic acid and Carcinoma, Non-Small Cell Lung
| Article | Year |
|---|---|
Addressing the elephant in the room, therapeutic resistance in non-small cell lung cancer, with epigenetic therapies.
Topics: Antibodies, Monoclonal; Azacitidine; Azetidines; Benzamides; Biomarkers, Tumor; Carcinoma, Non-Small | 2016 |
Topics: AC133 Antigen; Acenaphthenes; Acer; Acrosome Reaction; Adult; Agaricales; Aged; Aged, 80 and over; A | 2016 |
1 trial available for valproic acid and Carcinoma, Non-Small Cell Lung
| Article | Year |
|---|---|
Phase I study of 5-aza-2'-deoxycytidine in combination with valproic acid in non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Carcinoma, Non-Small-Cell | 2013 |
12 other studies available for valproic acid and Carcinoma, Non-Small Cell Lung
| Article | Year |
|---|---|
Tumors derived from lung cancer cells respond differently to treatment with sodium valproate (a HDAC inhibitor) in a chicken embryo chorioallantoic membrane model.
Topics: Animals; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Chick Embryo; Chickens; Chorioallantoic M | 2022 |
Erlotinib-Valproic Acid Liquisolid Formulation: Evaluating Oral Bioavailability and Cytotoxicity in Erlotinib-Resistant Non-small Cell Lung Cancer Cells.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Biological Availability; Calcium Compounds; Ca | 2019 |
Sodium valproate sensitizes non-small lung cancer A549 cells to γδ T-cell-mediated killing through upregulating the expression of MICA.
Topics: Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Gene Expression Regulation, Neoplastic; Histocompa | 2013 |
Potentiation of anticancer effect of valproic acid, an antiepileptic agent with histone deacetylase inhibitory activity, by the cyclin-dependent kinase inhibitor P276-00 in human non-small-cell lung cancer cell lines.
Topics: Acetylation; Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Cycle; | 2013 |
Sodium valproate, a histone deacetylase inhibitor, enhances the efficacy of vinorelbine-cisplatin-based chemoradiation in non-small cell lung cancer cells.
Topics: Anticonvulsants; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Non-Small-Cel | 2014 |
Synergistic antitumor activity of histone deacetylase inhibitors and anti-ErbB3 antibody in NSCLC primary cultures via modulation of ErbB receptors expression.
Topics: Antibodies, Monoclonal; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Cell Survival; Drug Syne | 2016 |
Valproic acid (VPA) enhances cisplatin sensitivity of non-small cell lung cancer cells via HDAC2 mediated down regulation of ABCA1.
Topics: Antineoplastic Agents; Apoptosis; ATP Binding Cassette Transporter 1; Carcinoma, Non-Small-Cell Lung | 2017 |
Dithiolethione modified valproate and diclofenac increase E-cadherin expression and decrease proliferation of non-small cell lung cancer cells.
Topics: Anethole Trithione; Animals; Cadherins; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proli | 2010 |
Downregulation of survivin and aurora A by histone deacetylase and RAS inhibitors: a new drug combination for cancer therapy.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aurora Kinases; Blotting, Wes | 2011 |
Inhibition of class I histone deacetylases in non-small cell lung cancer by honokiol leads to suppression of cancer cell growth and induction of cell death in vitro and in vivo.
Topics: Acetylation; Animals; Biphenyl Compounds; Bronchi; Carcinoma, Non-Small-Cell Lung; Cell Death; Cell | 2013 |
Efficacy of low-dose oral metronomic dosing of the prodrug of gemcitabine, LY2334737, in human tumor xenografts.
Topics: Administration, Metronomic; Administration, Oral; Animals; Carcinoma, Non-Small-Cell Lung; Cell Line | 2013 |
Valproic acid, an antiepileptic drug with histone deacetylase inhibitory activity, potentiates the cytotoxic effect of Apo2L/TRAIL on cultured thoracic cancer cells through mitochondria-dependent caspase activation.
Topics: Apoptosis; Apoptosis Regulatory Proteins; Carcinoma, Non-Small-Cell Lung; Caspases; Cell Line, Tumor | 2006 |